HSK50042 dose 1
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Haisco Pharmaceutical Group Co., Ltd.
Overview
HSK50042 dose 1 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
HSK50042 dose 1 clinical trials
Explore related
Medical disclaimer. This page summarizes research about HSK50042 dose 1 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.